白蛋白结合型紫杉醇联合粒细胞巨噬细胞集落刺激因子作为免疫调节剂治疗复发性铂耐药卵巢癌的II期试验
本II期试验纳入21例复发性铂耐药卵巢癌、腹膜癌或输卵管癌患者,接受白蛋白结合型紫杉醇(100mg/m2,第1、8、15天)后予粒细胞巨噬细胞集落刺激因子(GM-CSF,250μg,第16-26天),每28天为一周期,计划6周期。主要终点为与既往最近一次缓解相比的缓解持续时间。总缓解率72%,中位至进展时间4个月,中位总生存期16.8个月。作者认为该联合方案虽在多数患者中显示生化缓解但未能持续,且总生存期较既往白蛋白结合型紫杉醇单药研究无优势。
要点
- 21例复发性铂耐药卵巢癌患者接受白蛋白结合型紫杉醇联合GM-CSF治疗,总缓解率72%。
- 中位至进展时间4个月,仅10%患者缓解持续时间超过既往最近方案。
- 入组时髓源性抑制细胞较少与完全缓解显著相关(p=0.05)。
核心结论
- 白蛋白结合型紫杉醇联合GM-CSF在多数患者中显示生化缓解,但缓解未能持续。
- 该联合方案在总生存期上较既往白蛋白结合型紫杉醇单药研究无优势。
- 作者认为应研究调节髓源性抑制细胞的药物作为潜在辅助治疗,并继续探索扩增识别卵巢癌中具有生物学意义的肿瘤相关抗原的T细胞的策略。
研究设计与样本
- II期临床试验,纳入21例复发性铂耐药卵巢癌、腹膜癌或输卵管癌患者。
- 治疗方案:白蛋白结合型紫杉醇100mg/m2,第1、8、15天,随后GM-CSF 250μg,第16-26天,每28天为一周期,计划6周期。
- 主要终点为与既往最近一次缓解相比的缓解持续时间。
- 采用流式细胞术和干扰素-γ酶联免疫斑点法评估外周血。
主要发现
- 6例(29%)达到生化完全缓解,9例(43%)达到部分缓解,总缓解率72%。
- 中位至进展时间4个月,10%的患者缓解持续时间超过既往最近方案。
- 中位总生存期16.8个月。
- 入组时髓源性抑制细胞较少与完全缓解显著相关(p=0.05)。
- 治疗期间对IGF1R-p1332-1346的T细胞反应与至进展时间相关(r=0.827,p=0.0003),对IGF1R-p1242-1256的T细胞反应亦相关(r=0.850,p=0.0001)。
临床怎么用
- 作者认为应研究调节髓源性抑制细胞的药物作为潜在辅助治疗。
- 作者认为应继续研究扩增识别卵巢癌中具有生物学意义的肿瘤相关抗原的T细胞的策略。
局限性
- 缓解未能持续。
- 该联合方案在总生存期上较既往白蛋白结合型紫杉醇单药研究无优势。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Granulocyte macrophage colony-stimulating factor (GM-CSF) stimulates immunity via recruitment of antigen presenting cells and tumor specific T-cell stimulation. Albumin-bound paclitaxel (nab-paclitaxel) followed by GM-CSF may enhance antitumor responses and prolong remissions in ovarian cancer. Immune phenotypes present before treatment may identify responders to chemo-immunotherapy. METHODS: Recurrent platinum-resistant ovarian, peritoneal, or fallopian tube cancer patients received nab-paclitaxel, 100mg/m2 days 1, 8, 15 followed by GM-CSF 250μg days 16-26 every 28days for 6 planned cycles. The primary endpoint was remission duration compared to immediate prior remission. Peripheral blood was evaluated by flow cytometry and interferon-γ ELISPOT. RESULTS: Twenty-one patients were enrolled. Six patients (29%) achieved a biochemical complete response and 9 (43%) a partial response for an overall response rate of 72%. Median time to progression was 4months and 10% of patients achieved longer remissions than the immediate prior regimen. Median overall survival (OS) was 16.8months. Fewer myeloid derived suppressor cells (MDSC) at enrollment significantly associated with complete response (p=0.05). T-cell responses to IGF1R-p1332-1346 (r=0.827, p=0.0003) and IGF1R-p1242-1256 (r=0.850, p=0.0001) during treatment correlated with time to progression. CONCLUSIONS: Nab-paclitaxel combined with GM-CSF demonstrated biochemical responses in a majority of patients, although responses were not sustained. This combination did not demonstrate an advantage in OS over prior studies of nab-paclitaxel monotherapy. Agents that modulate MDSC should be studied as potential adjuvants to therapy. Strategies to expand T cells recognizing tumor-associated antigens biologically significant in ovarian cancer should also continue to be investigated.
引用
- Liao JB, Swensen RE, Ovenell KJ, et al. Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer. Gynecol Oncol. 2017. PMID: 28089377. doi:10.1016/j.ygyno.2017.01.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。